Drug intelligence / Profile preview

CRD1600

Development stage: Unknown
Lead developer: Curadev Therapeutics

Overview

CRD1600: sourced facts only. name: "CRD1600 is a potent, selective HPK-1 inhibitor that has been selected from a rich portfolio of active compounds and shows in vivo activity against the target." [DOI:10.1158/1538-7445.am2022-2122]; target: "CRD1600 is a potent, selective HPK-1 inhibitor that has been selected from a rich portfolio of active compounds and shows in vivo activity against the target." [DOI:10.1158/1538-7445.am2022-2122]; developer: "1Curadev Pharma, Noida, India;" [DOI:10.1158/1538-7445.am2022-2122]

Targets

MAP4K1 (Hematopoietic progenitor kinase 1)

Beyond the preview

Go deeper on CRD1600.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRD1600.